Herman MA, Jahr CE. Extracellular glutamate concentration in hippocampal slice. J Neurosci 27: 9736-9741

Oregon Health and Science University, Portland, Oregon, United States
The Journal of Neuroscience : The Official Journal of the Society for Neuroscience (Impact Factor: 6.34). 10/2007; 27(36):9736-41. DOI: 10.1523/JNEUROSCI.3009-07.2007
Source: PubMed


Synaptic glutamate transients resulting from vesicular exocytosis are superimposed on a low baseline concentration of glutamate in the extracellular space. Reported values of baseline glutamate concentrations range up to 4 microM. If glutamate were present tonically at low micromolar concentrations, many receptors, especially the high-affinity NMDA receptors (NMDARs), would be activated or desensitized, altering neuronal excitability. Using NMDARs expressed by CA1 pyramidal cells in acute hippocampal slices to monitor extracellular glutamate, we find that its baseline concentration is much lower, near 25 nM. In addition, superfusion of low micromolar concentrations of glutamate had no effect on neurons, indicating that glutamate transport prevents access to receptors within the slice. However, equipotent concentrations of NMDA, a nontransported agonist, depolarized neurons dramatically. We suggest that ambient concentrations of glutamate in vivo are also in the nanomolar range and are too low to cause significant receptor activation.

20 Reads
  • Source
    • "The presence of AMPARs may be important for responding to local activity-driven glutamate release and it has been proposed that glutamate transporters in Type 1 cells contribute to transmitter clearance (Regan and Smalley, 2007; Regan et al., 2007). However the functional impact of AMPARs and glutamate transporters in the absence of synaptic innervation needs further clarification since the ambient extracellular concentration of glutamate is extremely low (Herman and Jahr, 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The dentate gyrus is the entrance of the hippocampal formation and a primary target of excitatory afferents from the entorhinal cortex that carry spatial and sensory information. Mounting evidence suggests that continual adult neurogenesis contributes to appropriate processing of cortical information. The ongoing integration of adult born neurons dynamically modulates connectivity of the network, potentially contributing to dentate cognitive function. Here we review the current understanding of how glutamatergic innervation develops during the progression of adult-born neuron maturation. Summarizing the developmental stages of dentate neurogenesis, we also demonstrate that new neurons at an immature stage of maturation begin to process afferent activity from both medial and lateral entorhinal cortices. © 2015, Higher Education Press and Springer-Verlag Berlin Heidelberg.
    07/2015; 10(4). DOI:10.1007/s11515-015-1362-2
  • Source
    • "Microgliosis, the accumulation of activated microglia, is a characteristic pathological feature in many neurologic conditions such as trauma, stroke, inflammation, epilepsy, and neurodegenerative diseases (Cagnin et al., 2001; Eikelenboom et al., 2002; McGeer and McGeer, 2002; Nelson et al., 2002; Orr et al., 2002; Bruijn et al., 2004; Pavese et al., 2006). Activated microglia release massive amounts of glutamate, at much higher levels than astrocytes and neurons (mM vs. μM), and destroy neural cells; these processes have been implicated as a major cause of neuronal damage in neurologic diseases (Piani et al., 1992; Barger and Basile, 2001; Schwartz et al., 2003; Ye et al., 2003; Kipnis et al., 2004; Takeuchi et al., 2005, 2008b; Herman and Jahr, 2007; Liang et al., 2008; Yawata et al., 2008). Therefore, blockade of glutamate signaling and inhibition of microglial activation have been explored as therapeutic candidates for several neurodegenerative diseases. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Microglia are macrophage-like resident immune cells that contribute to the maintenance of homeostasis in the central nervous system (CNS). Abnormal activation of microglia can cause damage in the CNS, and accumulation of activated microglia is a characteristic pathological observation in neurologic conditions such as trauma, stroke, inflammation, epilepsy, and neurodegenerative diseases. Activated microglia secrete high levels of glutamate, which damages CNS cells and has been implicated as a major cause of neurodegeneration in these conditions. Glutamate-receptor blockers and microglia inhibitors (e.g., minocycline) have been examined as therapeutic candidates for several neurodegenerative diseases; however, these compounds exerted little therapeutic benefit because they either perturbed physiological glutamate signals or suppressed the actions of protective microglia. The ideal therapeutic approach would hamper the deleterious roles of activated microglia without diminishing their protective effects. We recently found that abnormally activated microglia secrete glutamate via gap-junction hemichannels on the cell surface. Moreover, administration of gap-junction inhibitors significantly suppressed excessive microglial glutamate release and improved disease symptoms in animal models of neurologic conditions such as stroke, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Recent evidence also suggests that neuronal and glial communication via gap junctions amplifies neuroinflammation and neurodegeneration. Elucidation of the precise pathologic roles of gap junctions and hemichannels may lead to a novel therapeutic strategies that can slow and halt the progression of neurodegenerative diseases.
    Frontiers in Cellular Neuroscience 09/2014; 8(189). DOI:10.3389/fncel.2014.00189 · 4.29 Impact Factor
  • Source
    • "In addition to pharmacological block of glutamate uptake leading to increased activation of AMPA and NMDA receptors (Jabaudon et al., 1999, 2000; Cavelier and Attwell, 2005; Le Meur et al., 2007; Herman and Jahr, 2007), ischemia-induced reversed transport also leads to large increases in extracellular [Glu] and pathological receptor signaling (Rossi et al., 2000). Changes are also predicted by the probe diffusion model probe as a consequence of increases in basal glutamate release (Fig. 4B 3 ). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Accurate knowledge of the ambient extracellular glutamate concentration in brain is required for understanding its potential impacts on tonic and phasic receptor signaling. Estimates of ambient glutamate based on microdialysis measurements are generally in the range of ∼2–10 μM, approximately 100-fold higher than estimates based on electrophysiological measurements of tonic NMDA receptor activity (∼25–90 nM). The latter estimates are closer to the low nanomolar estimated thermodynamic limit of glutamate transporters. The reasons for this discrepancy are not known, but it has been suggested that microdialysis measurements could overestimate ambient extracellular glutamate because of reduced glutamate transporter activity in a region of metabolically impaired neuropil adjacent to the dialysis probe. We explored this issue by measuring diffusion gradients created by varying membrane densities of glutamate transporters expressed in Xenopus oocytes. With free diffusion from a pseudo-infinite 10 μM glutamate source, the surface concentration of glutamate depended on transporter density and was reduced over 2 orders of magnitude by transporters expressed at membrane densities similar to those previously reported in hippocampus. We created a diffusion model to simulate the effect of transport impairment on microdialysis measurements with boundary conditions corresponding to a 100 μm radius probe. A gradient of metabolic disruption in a thin (∼100 μm) region of neuropil adjacent to the probe increased predicted [Glu] in the dialysate over 100-fold. The results provide support for electrophysiological estimates of submicromolar ambient extracellular [Glu] in brain and provide a possible explanation for the higher values reported using microdialysis approaches.
    Neurochemistry International 07/2014; 73(1). DOI:10.1016/j.neuint.2014.04.007 · 3.09 Impact Factor
Show more

Preview (2 Sources)

20 Reads
Available from